ISSN:1173-8324    

出版商:ADIS    

年代:2003

数据来源: ADIS

ISSN:1173-8324    

出版商:ADIS    

年代:2003

数据来源: ADIS

ISSN:1173-8324    

出版商:ADIS    

年代:2003

数据来源: ADIS

摘要:

Chronic myeloid leukaemia (CML) is associated with high healthcare resource use and treatment costs. In addition to drug acquisition costs and the relatively high hospitalisation rates for patients with CML compared with the general population, the need for administration of chemotherapy in a clinical setting contributes to the high price of treating CML. Thus, the use of an oral therapy suited to self-administration at home, such as imatinib mesylate ['Gleevec', 'Glivec', STI571], is expected to reduce the cost of treating CML, compared with standard chemotherapy. This hypothesis was supported by two studies presented at the 44th Annual Meeting of the American Society of Hematology [Philadelphia, US; December 2002]. An analysis of data from the IRIS*study showed that first-line treatment with imatinib was not only more effective, but also reduced inpatient and outpatient costs, compared with interferon (IFN)-α/cytarabine, thus offsetting its higher acquisition cost. A second study showed that imatinib was more cost effective than IFN-α/cytarabine in patients with chronic phase CML. The high cost of treating CML in elderly patients was confirmed by an analysis of US Medicare and outcomes data presented at the meeting. This study also suggested that elderly patients with CML were generally undertreated, with healthcare providers apparently reluctant to use chemotherapy in this population.

ISSN:1173-8324    

出版商:ADIS    

年代:2003

数据来源: ADIS

ISSN:1173-8324    

出版商:ADIS    

年代:2003

数据来源: ADIS

ISSN:1173-8324    

出版商:ADIS    

年代:2003

数据来源: ADIS

摘要:

Highly active antiretroviral therapy (HAART) has demonstrated the ability to suppress viral activity for extended periods and to prolong survival in patients with HIV infections. The proven efficacy of HAART has stimulated efforts to develop even more effective therapy, including more potent and better tolerated agents within existing drug classes and more convenient regimens. The protease inhibitor (PI) fosamprenavir [GW 433908], a water-soluble prodrug of amprenavir, allows for reductions in pill size and count, compared with the parent compound, factors that could improve patient compliance. The efficacy of fosamprenavir in treatment-experienced and antiretroviral-naive patients was demonstrated in two separate studies presented at the 10th Conference on Retroviruses and Opportunistic Infections [Boston, US; February 2003]. The first study, CONTEXT, demonstrated that the combination of fosamprenavir plus ritonavir was not inferior to lopinavir/ritonavir ['Kaletra'] in PI-experienced patients. Extended follow-up data from the NEAT study showed that fosamprenavir achieved better viral suppression than nelfinavir in treatment-naive patients. An analysis of resistance data from the NEAT and SOLO studies showed a lack of cross-resistance with other PIs, suggesting fosamprenavir was suitable for first-line use.

ISSN:1173-8324    

出版商:ADIS    

年代:2003

数据来源: ADIS

ISSN:1173-8324    

出版商:ADIS    

年代:2003

数据来源: ADIS

ISSN:1173-8324    

出版商:ADIS    

年代:2003

数据来源: ADIS

ISSN:1173-8324    

出版商:ADIS    

年代:2003

数据来源: ADIS